Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT1 receptor blockade

Biochemical and Biophysical Research Communications

Volumn 409, Issue 2, 2011, Pages 275-279

  Tsukuda, Kana ^a   Mogi, Masaki ^a   Iwanami, Jun ^a   Min, Li Juan ^a   Jing, Fei ^a   Oshima, Kousei ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Inflammation; Receptor; Stroke

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CARBOXYETHYLGERMANIUM SESQUIOXIDE; CHEMOKINE RECEPTOR CCR2; IRBESARTAN; LOSARTAN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG POTENTIATION; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; BRAIN ISCHEMIA; LOSARTAN; MALE; MICE; MICE, INBRED C57BL; ORGANOMETALLIC COMPOUNDS; RECEPTORS, CCR2; SIGNAL TRANSDUCTION; TETRAZOLES;

EID: 79957885653     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.142     Document Type: Article

References (24)

1. M. Horiuchi, M. Mogi, Roles of activation of angiotensin II receptor subtypes in ischemic brain damage and cognitive function, Br. J. Pharmacol. accepted for publication, doi:10.1111/j.1476-5381.2010.001167.x.
2. Fuentes B., Fernandez-Dominguez J., Ortega-Casarrubios M.A., SanJose B., Martinez-Sanchez P., Diez-Tejedor E. Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction. J. Hypertens. 2010, 28:575-581.
3. Kurtz T.W., Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens. Res. 2009, 32:826-834.
4. Morishita R., Kanda Y., Nakajima M. Irbesartan: second generation of ARB as metabosartan. Curr. Hypertens. Rev. 2010, 6:173-179.
5. Marshall T.G., Lee R.E., Marshall F.E. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor. Biol. Med. Model. 2006, 3:1.
6. Fujino M., Miura S., Kiya Y., Tominaga Y., Matsuo Y., Karnik S.S., Saku K. A small difference in the molecular structure of angiotensin II receptor blockers induces AT receptor-dependent and -independent beneficial effects. Hypertens. Res. 2010, 33:1044-1052.
7. Krege J.H., Hodgin J.B., Hagaman J.R., Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 1995, 25:1111-1115.
8. Tamura A., Graham D.I., McCulloch J., Teasdale G.M. Focal cerebral ischaemia in the rat: 1.Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1981, 1:53-60.
9. Qu K., Chen C.P., Halliwell B., Moore P.K., Wong P.T. Hydrogen sulfide is a mediator of cerebral ischemic damage. Stroke 2006, 37:889-893.
10. Bederson J.B., Pitts L.H., Germano S.M., Nishimura M.C., Davis R.L., Bartkowski H.M. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986, 17:1304-1308.
11. Hata R., Mies G., Wiessner C., Fritze K., Hesselbarth D., Brinker G., Hossmann K.A. A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J. Cereb. Blood Flow Metab. 1998, 18:367-375.
12. Mogi M., Iwai M., Horiuchi M. New insights into the regulation of angiotensin receptors. Curr. Opin. Nephrol. Hypertens. 2009, 18:138-143.
13. Usui M., Egashira K., Tomita H., Koyanagi M., Katoh M., Shimokawa H., Takeya M., Yoshimura T., Matsushima K., Takeshita A. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000, 101:305-310.
14. Henkel T., Machleidt T., Alkalay I., Kronke M., Ben-Neriah Y., Baeuerle P.A. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature 1993, 365:182-185.
15. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002.
16. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054-2057.
17. Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martinez A., Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 2005, 280:21453-21462.
18. Wang N., Verna L., Chen N.G., Chen J., Li H., Forman B.M., Stemerman M.B. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 2002, 277:34176-34181.
19. Klotz L., Sastre M., Kreutz A., Gavrilyuk V., Klockgether T., Feinstein D.L., Heneka M.T. Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. J. Neurochem. 2003, 86:907-916.
20. Iwanami J., Mogi M., Tsukuda K., Min L.J., Sakata A., Jing F., Iwai M., Horiuchi M. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. J. Hypertens. 2010, 28:1730-1737.
21. Tsukuda K., Mogi M., Iwanami J., Min L.J., Sakata A., Jing F., Iwai M., Horiuchi M. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009, 54:782-787.
22. Washida K., Ihara M., Nishio K., Fujita Y., Maki T., Yamada M., Takahashi J., Wu X., Kihara T., Ito H., Tomimoto H., Takahashi R. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke 2010, 41:1798-1806.
23. Matsumura T., Kinoshita H., Ishii N., Fukuda K., Motoshima H., Senokuchi T., Taketa K., Kawasaki S., Nishimaki-Mogami T., Kawada T., Nishikawa T., Araki E. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-{gamma} in macrophages. Arterioscler. Thromb. Vasc. Biol. 2011.
24. Iwai M., Kanno H., Senba I., Nakaoka H., Moritani T., Horiuchi M. Irbesartan increased PPARgamma activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction. Biochem. Biophys. Res. Commun. 2011, 406:123-126.